8-K/A - SDEV - Equibles

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K/A

AMENDMENT NO. 1

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 1, 2021 (November 5, 2021)

NovaBay Pharmaceuticals, Inc.

(Exact Name of Registrant as Specified in Charter)

Delaware	001-33678	68-0454536
(State or Other Jurisdiction<br><br> <br>of Incorporation)	(Commission File Number)	(I.R.S. Employer<br><br> <br>Identification No.)

2000 Powell Street, Suite 1150, Emeryville, CA 94608

(Address of Principal Executive Offices) (Zip Code)

(510) 899-8800

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class	Trading Symbol(s)	Name of Each Exchange On Which<br><br> <br>Registered
Common Stock, par value $0.01 per share	NBY	NYSE American

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

INTRODUCTORY NOTE

This Amendment No. 1 to Current Report on Form 8-K/A (“Amendment No. 1”) amends the Current Report on Form 8-K of NovaBay Pharmaceuticals, Inc., a Delaware corporation (the “Company”), filed on November 12, 2021 (the “Original Report”), in which the Company reported the completion of the acquisition of DERMAdoctor, LLC, a Missouri limited liability company (“DERMAdoctor”) pursuant to the Membership Unit Purchase Agreement, dated September 27, 2021 (the “DERMAdoctor Acquisition”).

This Amendment No. 1 is being filed in order to provide (a) the historical audited balance sheets of DERMAdoctor as of December 31, 2020 and 2019 and the related audited statements of income, cash flows, and members’ deficiency for each of the years in the two years ended December 31, 2020, (b) the historical unaudited balance sheet of DERMAdoctor as of September 30, 2021 and the related unaudited statements of income for the nine months ended September 30, 2021 and 2020, and (c) the unaudited pro forma condensed combined financial information as of and for the nine months ended September 30, 2021 and for the year ended December 31, 2020, in connection with the completion of the DERMAdoctor Acquisition.

This Amendment No. 1 does not amend any other item of the Original Report or purport to provide any update, modification or discussion of any developments or events with respect to the Company subsequent to the filing date of the Original Report. The information previously reported in, or filed with, the Original Report is hereby incorporated by reference into this Amendment No. 1.

Item 9.01 Financial Statements and Exhibits

(a) Financial Statements of Businesses Acquired

The historical audited balance sheets of DERMAdoctor as of December 31, 2020 and 2019 and the related audited statements of income, cash flows, and members’ deficiency for each of the years in the two years ended December 31, 2020, and the related notes thereto and the report of accounting firm thereon, are filed as Exhibit 99.1 to this Amendment No. 1.

The historical unaudited balance sheet of DERMAdoctor as of September 30, 2021 and the related unaudited statements of income for the nine months ended September 30, 2021 and 2020 are filed as Exhibit 99.2 to this Amendment No. 1.

(b) Pro Forma Financial Information

The following unaudited pro forma financial information of the Company is filed as Exhibit 99.3 to this Amendment No. 1.

●	Unaudited Pro Forma Condensed Combined Balance Sheet as of September 30, 2021;
●	Unaudited Pro Forma Condensed Combined Statement of Operations for the nine months ended September 30, 2021;
---	---
●	Unaudited Pro Forma Condensed Combined Statement of Operations for the year ended December 31, 2020; and
---	---
●	Notes to the Unaudited Pro Forma Condensed Combined Financial Statements.
---	---

Cautionary Language Concerning Forward-Looking Statements

The pro forma financial information in Exhibit 99.3 contains forward looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial progress and future financial performance of the Company. Accordingly, this Amendment No. 1 contains forward-looking statements that are based upon management’s current expectations, assumptions, estimates, projections and beliefs. These statements include, but are not limited to, statements regarding our current product offerings and marketing efforts, the financial impact of the Company’s recently completed private placement transaction on November 2, 2021, including the use of proceeds, and the DERMAdoctor Acquisition, our partnerships, and any future revenue that may result from selling our products, as well as generally the Company’s expected future financial results. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results or achievements to be materially different and adverse from those expressed in or implied by these forward-looking statements. Other risks relating to the Company’s business, including risks that could cause results to differ materially from those projected in the forward-looking statements in this Amendment No. 1, are detailed in the Company’s latest Form 10-K, and the subsequent Definitive Proxy Statements, Forms 10-Q and/or Form 8-K filings with the Securities and Exchange Commission, especially under the heading “Risk Factors.” The forward-looking statements in this Amendment No. 1 speak only as of this date, and the Company disclaims any intent or obligation to revise or update publicly any forward-looking statement except as required by law.

(d) Exhibits

Exhibit No.	Description
23.1	Consent of MarksNelson LLC
99.1	Audited financial statements of DERMAdoctor, LLC for the years ended December 31, 2020 and 2019 (incorporated by reference to Exhibit 99.1 of NovaBay's Current Report on Form 8-K filed November 2, 2021)
99.2	Unaudited financial statements of DERMAdoctor, LLC for the nine months ended September 30, 2021
99.3	Unaudited pro forma condensed combined financial information of NovaBay Pharmaceuticals, Inc.
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

NovaBay Pharmaceuticals, Inc.
By:	/s/ Justin M. Hall
	Justin M. Hall
	Chief Executive Officer and General Counsel

Dated: December 1, 2021

ex_311599.htm

Exhibit 23.1

Consent of MarksNelson Independent Public Accounting Firm

We have issued our report, dated July 26, 2021, with respect to the financial statements of DERMAdoctor, LLC for the years ended December 31, 2020 and 2019 (the “DERMAdoctor Financial Statements”), which have been included in the Amendment No. 1 to the Current Report on Form 8-K of NovaBay Pharmaceuticals, Inc. (“NovaBay”), filed with the Securities and Exchange Commission (“SEC”) on December 1, 2021 (the “Form 8-K/A”).

We hereby consent to (1) the inclusion of the DERMAdoctor Financial Statements in the Form 8-K/A, (2) the incorporation by reference of the DERMAdoctor Financial Statements in the Registration Statements of NovaBay on Form S-8 (File Nos. 333-252155, 333-236328, 333-222625, 333-218469, 333-215680, 333-211754, 333-208985, 333-203109, 333-196764, 333-194383, 333-185998, 333-180461, 333-171981, 333-147334, 333-157041, and 333-164469), Form S-3 (File Nos. 333-254744, 333-248238, 333-233623, 333-232860, 333-230672, 333-211944 and 333-211943) and Form S-1 (File Nos. 333-238317 and 333-234330) and (3) the reference to our firm under the caption “Experts” in a Prospectus Supplement and/or amendment to the Form S-3 (File No. 333-254744). This consent also includes all amendments and supplements to these NovaBay filings with the SEC.

/s/ MarksNelson LLC

Kansas City, Missouri

December 1, 2021

HTML Editor

Exhibit 99.2

DERMAdoctor, LLC Unaudited Balance Sheets as of September 30, 2021 and 2020

	September 30, 2021		September 30, 2020
Assets	****	****	****	****	****
Cash and cash equivalents	$	1,440	$	3,871
Accounts receivable		1,092,614		567,851
Inventory, net		2,672,494		3,311,955
Prepaid expenses		16,431		31,954
Total current assets		3,782,979		3,915,631
Property and equipment, net		56,956		75,324
Intangibles, net		65,546		125,399
Total assets	$	3,905,481	$	4,116,354
Liabilities and Equity	****	****	****	****	****
Liabilities	****	****	****	****	****
Checks written in advance of deposits	$	-	$	34,627
Related party notes payable		1,645,000		1,690,000
Paycheck Protection Program Loan		-		315,800
Accounts payable		38,138		436,344
Related party accounts payable		45,000		45,000
Accrued expense and other current liabilities		899,340		1,070,066
Total current liabilities		2,627,478		3,591,837
Total liabilities		2,627,478		3,591,837
Equity	****	****	****	****	****
Redeemable membership interest		1,270,000		1,270,000
Members' equity (deficiency)		8,003		(745,483	)
Total Equity		1,278,003		524,517
Total liabilities, redeemable membership interest and members' equity (deficiency)	$	3,905,481	$	4,116,354

DERMAdoctor, LLC Unaudited Income Statements for the Nine Months Ended September 30, 2021 and 2020

	For the 9 months ended			For the 9 months ended
	September 30, 2021			September 30, 2020
Net sales	$	4,604,089		$	6,781,592
Cost of sales		1,800,938			3,204,146
Gross Profit		2,803,151			3,577,446
Operating expenses
Selling expenses		1,226,173			1,516,048
General and administrative expenses		1,075,567			1,064,910
Total Expenses		2,301,740			2,580,958
Income from operations		501,411			996,488
Other income (expense), net		602,503			(3,979	)
Interest Expense		(92,483	)		(96,274	)
Net income	$	1,011,431		$	896,235

DERMAdoctor, LLC Unaudited Statements of Cash Flows for the Nine Months Ended September 30, 2021 and 2020

	For the 9 months ended			For the 9 months ended
	September 30, 2021			September 30, 2020
Cash flows from operating activities:
Net income	$	1,011,431		$	896,235
Adjustments to reconcile net income to net cash provided by operating activities
Depreciation of property and equipment		13,563			20,026
Amortization of intangibles		34,700			28,862
Other income recognized on forgiveness of payroll protection program loan		(602,500	)		-
Changes in operating assets and liabilities:
Accounts receivable		(877,767	)		171,273
Inventory, net		209,924			(833,832	)
Prepaid expenses		3,548			1,302
Contract assets		-			145,079
Checks written in advance of deposits		(39,377	)		(236,483	)
Accounts payable		(180,747	)		62,788
Accrued expenses and other liabilites		495,661			(42,683	)
Net cash provided by operating activities		68,436			212,567
Cash flows from investing activities:
Purchases of property and equipment		-			(12,231	)
Purchases of intangibles		-			(34,580	)
Net cash used in investing activities		-			(46,811	)
Cash flows from financing activities:
Net proceeds (repayment) on lines of credit		(324,477	)		(482,572	)
Repayments of related party notes payable		(45,000	)		-
Proceeds from payroll protection program loan		286,700			315,800
Net cash used in financing activities		(82,777	)		(166,772	)
Net (decrease) in cash		(14,341	)		(1,016	)
Cash - Beginning of period		15,781			4,887
Cash - End of period	$	1,440		$	3,871
Supplemental disclosure of cash and non-cash investing and financing transactions
Cash paid for interest	$	92,843		$	96,274

ex_311601.htm

Exhibit 99.3

UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION

Introduction

The following unaudited pro forma condensed combined financial information is presented to illustrate the estimated effect of the recently completed acquisition (the “DERMAdoctor Acquisition”) by NovaBay Pharmaceuticals, Inc. (“NovaBay”, “we”, “our” and “us”) of DERMAdoctor, LLC (“DERMAdoctor”) pursuant to the terms of the Membership Unit Purchase Agreement, dated September 27, 2021 (the “Acquisition Purchase Agreement”), by and among (i) NovaBay, (ii) DERMAdoctor, (iii) Dr. Jeffrey Kunin and Dr. Audrey Kunin (the “Founders”), (iv) Papillon Partners, Inc., a Missouri corporation that is owned by the Founders (“Papillon”) and (v) Midwest Growth Partners, L.L.L.P., an Iowa limited liability limited partnership (together with Papillon, the “Sellers”), for the purchase price of approximately $15.0 million (the “Purchase Price”). The DERMAdoctor Acquisition closed on November 5, 2021 (the “Acquisition Closing”). The Purchase Price was comprised of a payment to the Sellers of approximately $12.0 million in cash at the Acquisition Closing, which amount was (x) reduced by amounts paid to satisfy DERMAdoctor’s indebtedness and its transaction expenses as of the Acquisition Closing, and (y) increased by the amount of remaining DERMAdoctor cash and cash equivalents as of the Acquisition Closing. In addition, $1.2 million of the Purchase Price paid at the Acquisition Closing was deposited into an escrow account, which amount is available to NovaBay to satisfy indemnification obligations of the Founders and the Sellers in accordance with the Acquisition Purchase Agreement. The remaining amount of the Purchase Price is comprised of up to an aggregate of $3.0 million in earn out payments, which are contingent upon the legacy DERMAdoctor business achieving predetermined financial targets for the 2022 and the 2023 calendar years (the “Earn Out Payments”).

The unaudited pro forma condensed combined financial information also presents the pro forma effects of our private placement of 15,000 shares of our Series B Non-Voting Convertible Preferred Stock, par value $0.01 per share (the “Preferred Stock”), convertible into an aggregate of 37,500,000 shares of NovaBay common stock, par value $0.01 per share (the “Common Stock”), and Common Stock warrants (the “Warrants”) exercisable for an aggregate of 37,500,000 shares of Common Stock, which we completed on November 2, 2021 (the “Private Placement”). We received gross proceeds of $15.0 million in the Private Placement, which proceeds were partially used to fund the Purchase Price at the Acquisition Closing.

The unaudited pro forma condensed combined financial information presented has been prepared in accordance with Article 11 of Regulation S-X, Pro Forma Financial Information, as amended by the SEC’s final rule, Release No. 33-10786 “Amendments to Financial Disclosures about Acquired and Disposed Businesses,” and are being provided pursuant to Rule 3-05 of Regulation S-X as a result of the DERMAdoctor Acquisition having been completed.

Release No. 33-10786 replaces the existing pro forma adjustment criteria with simplified requirements to depict the accounting for the transaction (the “Transaction Accounting Adjustments”) and the option to present the reasonably estimable synergies and other transaction effects that have occurred or are reasonably expected to occur (“Management’s Adjustments”). NovaBay has elected not to present Management’s Adjustments and has only presented Transaction Accounting Adjustments in the following unaudited pro forma condensed combined financial information.

The unaudited pro forma condensed combined balance sheet as of September 30, 2021 combines the historical balance sheets of NovaBay and DERMAdoctor on a pro forma basis giving effect to the DERMAdoctor Acquisition and Private Placement as if they had been completed on September 30, 2021. The unaudited pro forma condensed combined statements of operations for the nine months ended September 30, 2021 and for the year ended December 31, 2020 combine the historical statements of operations of NovaBay and DERMAdoctor giving effect to the DERMAdoctor Acquisition and Private Placement as if they had been completed on January 1, 2020, the earliest period presented.

The pro forma adjustments and allocation of the Purchase Price are preliminary, are based on management’s current estimates of the fair value of the acquired assets and assumed liabilities, and are based on currently available information, including preliminary work performed by independent valuation specialists. In addition to the DERMAdoctor Acquisition, the unaudited pro forma condensed combined financial information provides for the anticipated effects of and the use of proceeds from the Private Placement.

As of the date of this Amendment No. 1, we have not completed the detailed valuation analysis and calculations necessary to arrive at final estimates of the fair market value of the assets of DERMAdoctor to be acquired and the liabilities to be assumed and the related allocations of the Purchase Price, nor have we identified all adjustments necessary to conform DERMAdoctor’s accounting policies to our accounting policies. Accordingly, certain of DERMAdoctor’s assets and liabilities are presented at their respective carrying amounts and should be treated as preliminary values.

Actual results will differ from the unaudited pro forma condensed combined financial information provided herein once we have completed the valuation analysis necessary to finalize the required Purchase Price allocations and identified any additional conforming accounting policy changes for DERMAdoctor. There can be no assurance that such finalization will not result in material changes to the unaudited pro forma condensed combined financial information presented.

There can be no assurance that such finalization of the items above will not result in material changes to the unaudited pro forma condensed combined financial information presented.

Assumptions and estimates underlying the unaudited pro forma adjustments set forth in the unaudited pro forma condensed combined financial statements are described in the accompanying notes below. The unaudited pro forma adjustments represent management’s estimates based on information available as of the date of these unaudited pro forma condensed combined financial statements and are subject to change as additional information becomes available and analyses are performed.

The unaudited pro forma condensed combined financial information and accompanying notes are based on, and should be read in conjunction with, (i) the historical audited consolidated financial statements of NovaBay and accompanying notes for the year ended December 31, 2020, which are included in our Annual Report on Form 10-K filed with the SEC on March 25, 2021 and the historical unaudited consolidated financial statements of NovaBay and accompanying notes for the period ended September 30, 2021, which are included in our Quarterly Report on Form 10-Q filed with the SEC on November 12, 2021, (ii) the historical audited financial statements of DERMAdoctor and accompanying notes included for the year ended December 31, 2020 and the historical unaudited financial statements of DERMAdoctor and accompanying notes for the nine-month period ended September 30, 2021, each of which are included in this Amendment No. 1.

The following unaudited pro forma condensed combined financial statements are provided for illustrative purposes only and are based on currently available information and assumptions that we believe are reasonable under the circumstances. They do not purport to represent what our actual consolidated results of operations or the consolidated financial position would have been had the DERMAdoctor Acquisition and Private Placement been completed on the dates indicated, or on any other date, nor are they necessarily indicative of our future consolidated results of operations or consolidated financial position after the DERMAdoctor Acquisition is completed. Accordingly, our actual financial position and results of operations will differ, perhaps significantly, from the pro forma amounts reflected herein due to a variety of factors, including changes in value not currently identified and changes in operating results of NovaBay and DERMAdoctor following the date of the unaudited pro forma condensed combined financial statements.

Unaudited Pro Forma Condensed Combined Balance Sheet

As of September 30, 2021

(in thousands)

	NovaBay<br><br> <br>Pharmaceuticals,<br><br> <br>Inc.		DERMAdoctor, LLC		Transaction<br><br> <br>Accounting<br><br> <br>Adjustments			Other Transaction<br><br> <br>Adjustments		Notes	Pro Forma<br><br> <br>Combined
ASSETS	****	****	****	****	****	****	****	****	****		****	****
Cash and cash equivalents	$	9,028	$	1	$	(12,000	)	$	13,375	(j)	$	10,404
Accounts receivable, net of allowance for doubtful accounts		843		1,093								1,936
Inventory, net of allowance		969		2,672								3,641
Prepaid expenses and other current assets		657		17								674
Total current assets		11,497		3,783		(12,000	)		13,375			16,655
Operating lease right-of-use assets		170		-								170
Intangible assets, net		-		66		2,960				(a) (i)		3,026
Goodwill		-		-		6,452				(b)		6,452
Property and equipment, net		96		57								153
Other assets		476		-								476
TOTAL ASSETS	$	12,239	$	3,906	$	(2,588	)	$	13,375		$	26,932
LIABILITIES AND STOCKHOLDERS' EQUITY	****	****	****	****	****	****	****	****	****		****	****
Accounts payable	$	1,354	$	38							$	1,392
Related party accounts payable		-		45	$	(45	)			(d)		-
Accrued liabilities		1,325		900								2,225
Fair value of earn-out payments		-		-		750				(c)		750
Related party notes payable		-		1,645		(1,645	)			(d)		-
Operating lease liability		195		-								195
Total current liabilities		2,874		2,628		(940	)					4,562
Operating lease liability- non-current		1		-								1
TOTAL LIABILITIES	$	2,875	$	2,628	$	(940	)				$	4,563
Convertible preferred stock	$	-	$	-				$	13,375	(j)	$	13,375
Total stockholders' equity (1)	$	9,364	$	1,278	$	(1,648	)			(e) (i)	$	8,994
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$	12,239	$	3,906	$	(2,588	)	$	13,375		$	26,932

(1) - Presented as “Total equity” in DERMAdoctor’s financial statements as of September 30, 2021

Unaudited Pro Forma Condensed Combined Statement of Operations

For the nine-months ended September 30, 2021

(in thousands)

	NovaBay Pharmaceuticals, Inc.			DERMAdoctor, LLC		Transaction Accounting Adjustments			Notes	Pro Forma Combined
Sales:
Product revenue, net	$	5,761		$	4,604	$	(449	)	(f)	$	9,916
Other revenue, net		19			-						19
Total sales, net		5,780			4,604		(449	)			9,935
Cost of goods sold		1,562			1,801						3,363
Gross Profit		4,218			2,803		(449	)			6,572
Operating expenses:
Research and development		36			-						36
Sales and marketing		5,323			1,226		(449	)	(f)		6,100
General and administrative expenses		4,527			1,076		(697	)	(h)		4,906
Amortization of intangibles		-			-		159		(i)		159
Total operating expenses		9,886			2,302		(987	)			11,201
Operating net income (loss)		(5,668	)		501		538				(4,629	)
Other income (expense), net		2			510		(316	)	(g)		196
Net income (loss) before provision for income taxes		(5,666	)		1,011		222				(4,433	)
Net Income (loss) and comprehensive net income (loss)	$	(5,666	)	$	1,011	$	222			$	(4,433	)
Net loss per share (basic)	$	(0.13	)							$	(0.10	)
Net loss per share (diluted)	$	(0.13	)							$	(0.10	)
Weighted-average shares of common stock (basic)		43,100									43,100
Weighted average shares of common stock (diluted)		43,100									43,100

Unaudited Pro Forma Condensed Combined Statement of Operations

For the year ended December 31, 2020

(in thousands)

	NovaBay<br><br> <br>Pharmaceuticals,<br><br> <br>Inc.			DERMAdoctor,<br><br> <br>LLC			Transaction<br><br> <br>Accounting<br><br> <br>Adjustments			Notes	Pro Forma<br><br> <br>Combined
Sales:
Product revenue, net	$	9,916		$	8,387		$	(202	)	(f)	$	18,101
Other revenue, net		18			-							18
Total sales, net		9,934			8,387			(202	)			18,119
Cost of goods sold		3,970			4,133							8,103
Gross Profit		5,964			4,254			(202	)			10,016
Operating expenses:
Research and development		285			-							285
Sales and marketing		6,173			1,983			(202	)	(f)		7,954
General and administrative expenses		5,932			1,499							7,431
Amortization of intangibles		-			-			211		(i)		211
Total operating expenses		12,390			3,482			9				15,881
Operating net income (loss)		(6,426	)		772			(211	)			(5,865	)
Non-cash (loss) on changes in fair value of warrant liability		(5,216	)		-							(5,216	)
Non-cash gain on changes in fair value of embedded derivative liability on changes in fair value of warrant liability		3			-							3
Other income (expense), net		605			(133	)		316		(g)		788
Net income (loss) before provision for income taxes		(11,034	)		639			105				(10,290	)
Provision for income taxes		(5	)		-							(5	)
Net Income (loss) and comprehensive net income (loss)	$	(11,039	)	$	639		$	105			$	(10,295	)
Net loss per share (basic)	$	(0.31	)								$	(0.29	)
Net loss per share (diluted)	$	(0.31	)								$	(0.29	)
Weighted-average shares of common stock (basic)		35,076										35,076
Weighted average shares of common stock (diluted)		35,076										35,076

Note 1. Basis of Pro Forma Presentation

The unaudited pro forma condensed combined financial statements are derived from the historical consolidated financial statements of NovaBay and the historical financial statements of DERMAdoctor. The unaudited pro forma condensed combined financial statements are prepared as a business combination using the purchase accounting method.

The unaudited pro forma condensed combined balance sheet has been prepared to reflect the transaction as if the DERMAdoctor Acquisition had been completed on September 30, 2021. The unaudited pro forma condensed combined statements of operations for the nine months ended September 30, 2021 and for the year ended December 31, 2020 combine the historical statements of operations of NovaBay and DERMAdoctor giving effect to the DERMAdoctor Acquisition as if it had been completed on January 1, 2020, the earliest period presented.

The DERMAdoctor Acquisition will be accounted for under the purchase accounting method of accounting in accordance with FASB ASC 805, Business Combinations, using the fair value concepts defined in ASC 820, Fair Value Measurements and Disclosures. We are treated as the “acquirer” and DERMAdoctor is treated as the “acquired” company for financial reporting purposes. Accordingly, the purchase consideration allocated to the DERMAdoctor business’s assets and liabilities for preparation of the unaudited pro forma condensed combined sheet is based upon its estimated preliminary fair values assuming the DERMAdoctor Acquisition was completed as of September 30, 2021. The amount of the purchase consideration that was in excess of the estimated preliminary fair values of the DERMAdoctor business’s net assets and liabilities at September 30, 2021 is recorded as goodwill in the unaudited pro forma condensed combined balance sheet.

We have not yet performed the detailed valuation studies necessary to arrive at the final estimates of the fair value of DERMAdoctor’s acquired assets, the assumed liabilities and the related allocations of the Purchase Price.

The unaudited pro forma condensed financial information includes pro forma adjustments that are (i) directly attributable to the DERMAdoctor Acquisition, (ii) factually supportable, and (iii) with respect to the unaudited condensed pro forma statements of operations, expected to have a continuing impact on the results of operations of the combined company.

Actual results may differ from these unaudited pro forma condensed combined financial statements once we have determined the final Purchase Price for DERMAdoctor and have completed the valuation studies necessary to finalize the required Purchase Price allocations and identified any additional conforming accounting policy changes for DERMAdoctor. There can be no assurance that such finalization will not result in material changes to the unaudited pro forma condensed combined financial information presented. The preliminary unaudited pro forma Purchase Price allocation has been made solely for preparing these unaudited pro forma condensed combined financial statements.

Additionally, we have not yet completed a detailed analysis of the accounting impact of the Private Placement and therefore, the pro forma presentation of the Private Placement is also preliminary. Actual results will differ from the unaudited pro forma condensed combined financial information provided herein once we have completed a detailed analysis. These unaudited pro forma condensed combined financial statements are presented for illustrative purposes only and do not give effect to any cost savings from operating efficiencies, revenue synergies, differences in stand-alone costs of the DERMAdoctor business or costs for the integration of DERMAdoctor’s business operations with NovaBay. These unaudited pro forma condensed combined financial statements do not purport to represent what the actual consolidated results of operations of NovaBay would have been had the DERMAdoctor Acquisition been completed on the dates assumed, nor are they necessarily indicative of future consolidated results of operations or consolidated financial position. Any transaction, separation or integration costs will be expensed in the appropriate accounting periods after completion of the DERMAdoctor Acquisition.

Note 2. Accounting Policies

The unaudited pro forma condensed combined financial statements may not reflect all reclassifications necessary to conform DERMAdoctor’s presentation to that of NovaBay’s due to limitations on the availability of information as of the date of this Amendment No. 1. As a result of the completion of the DERMAdoctor Acquisition, we will further review DERMAdoctor’s accounting policies. As a result of that review, we may identify differences between the accounting policies of the two companies that, when conformed, could have a material impact on the combined financial statements.

Note 3. Preliminary Purchase Consideration and Purchase Price Allocation

Under the purchase method of accounting, the identifiable assets acquired and liabilities assumed are recorded at the fair values. The Purchase Price allocation provided in these unaudited pro forma condensed combined financial statements is preliminary and based on estimates of the fair value as of September 30, 2021 and not the actual date of the Acquisition Closing.

We have engaged a third-party valuation company to assist us with the valuation of DERMAdoctor and its assets and liabilities. The detailed valuation necessary to estimate the fair value of the assets acquired and liabilities assumed has not yet been completed; accordingly, the adjustments to record the assets acquired and liabilities assumed at fair value reflect the best estimate of NovaBay based on the information currently available and are subject to change once additional analyses are completed.

There can be no assurance that such third-party valuation work will not result in material changes from the preliminary accounting treatment included in the accompanying unaudited pro forma condensed combined financial statements.

The Purchase Price as provided in the Acquisition Purchase Agreement provides for the Sellers to receive up to $15.0 million in connection with the DERMAdoctor Acquisition, of which $12.0 million in cash was paid at the Acquisition Closing and up to $3.0 million in Earn Out Payments may become payable to the Sellers in the future if the legacy DERMAdoctor business achieves predetermined financial targets for the 2022 and the 2023 calendar years. In addition, $1.2 million of the Purchase Price at the Acquisition Closing was deposited into an escrow account, which amount is available to NovaBay to satisfy indemnification obligations of the Founders and the Sellers in accordance with the Acquisition Purchase Agreement. As a result of the contingent nature of the Earn Out Payments and for purposes of the unaudited pro forma condensed combined financial statements, we have estimated the total amount for the DERMAdoctor Acquisition to be $12.75 million, comprised of a cash payment of $12.0 million and $750,000 for the preliminary estimated fair value of the Earn Out Payments.

	Amount
Cash transferred	$	12,000,000
Estimated fair value of Earn Out payments		750,000
Estimated fair value of consideration transferred	$	12,750,000

The estimated fair value of the Earn Out Payments is preliminary and based upon available information and certain assumptions, known at the time of this report, which management believes are reasonable. This preliminary fair value estimate for the Earn Out Payments may change as additional information becomes available and such changes could be material. Upon final determination of the fair value of the Earn Out Payments, any differences in the actual Earn Out Payments will be recorded in operating income (expense) in the consolidated statements of operations.

The table below represents a preliminary allocation of the estimated total Purchase Price to the DERMAdoctor business’s assets and liabilities in the DERMAdoctor Acquisition based on our preliminary estimate of their respective fair values:

Description	Fair Value ( in thousands)
Assets acquired:
Cash and cash equivalents	$	1
Accounts receivable, net of allowance for doubtful accounts		1,093
Inventory, net of allowance		2,672
Prepaid expenses and other current assets		17
Property and equipment, net		57
Intangible assets		3,396
Goodwill		6,452
Total assets acquired	$	13,688
Liabilities assumed:
Accounts payable	$	38
Accrued liabilities		900
Total liabilities acquired		938
Estimated fair value of net assets acquired	$	12,750

Goodwill represents the amount of the Purchase Price in excess of the estimated preliminary amounts assigned to the fair value of the DERMAdoctor assets acquired and the liabilities assumed. Since these amounts are estimates, the final amount of goodwill recorded may differ materially from the amount presented.

Our unaudited preliminary allocation of the estimated total Purchase Price includes certain identifiable intangible assets with an estimated fair value of approximately $3.3 million. Customer relationships and trade secrets / product formulation are expected to have a finite life and are expected to be amortized using the straight-line method over the respective lives of each asset, while trade name is not expected to be amortized. Trade name will be tested for impairment at least annually for events or circumstances that may indicate a possible impairment exists.

Goodwill is expected to be recorded for the excess of the consideration transferred over the preliminary fair value of the assets acquired and liabilities assumed. Goodwill will not be amortized, but instead will be tested for impairment at least annually for events or circumstances that may indicate a possible impairment exists. In the event management determines that the value of goodwill has been impaired, we will incur an impairment charge during the period in which the determination is made.

Intangible Asset	Fair Value (in thousands)		Useful Life	Amortization Method
Customer Relationships	$	160	6.5 Years	Straight line
Trade Secrets / Product Formulation		840	4.5 Years	Straight line
Trade Name		2,330	Indefinite	N/A
Goodwill		6,452	Indefinite	N/A
	$	9,782

The unaudited pro forma condensed combined statements of operations for the nine months ended September 30, 2021 and for the year ended December 31, 2020 include pro forma adjustments related to the amortization of the intangible assets acquired. For pro forma purposes, the finite life intangible assets are amortized on a straight-line basis beginning on January 1, 2020, as if the DERMAdoctor Acquisition occurred on that date.

The preliminary fair value of the identifiable intangible assets acquired was estimated using a combination of asset-based and income-based valuation methodologies. The asset-based valuation methodology established a fair value estimate based on the cost of replacing the asset, less amortization from functional use and economic obsolescence, if present and measurable. The income-based valuation methodology utilizes a discounted cash flow technique where the expected future economic benefits of ownership of an asset are discounted back to present value. This valuation technique requires us to make certain assumptions about future operating performance and cash flow, and other such variables which are discounted to present value using a discount rate that reflects the risk factors associated with future cash flow, the characteristics of the assets acquired, and the experience of the acquired business. Such valuation methodologies and estimates are subject to change, possibly materially, as additional information becomes available and as additional analyses are performed.

The unaudited preliminary allocation of the estimated Purchase Price has been made solely for the purpose of preparing these unaudited pro forma condensed combined financial statements.

The final total consideration and amounts allocated to DERMAdoctor’s acquired assets and assumed liabilities could differ materially from the preliminary amounts presented in these unaudited pro forma condensed combined financial statements. A decrease in the fair value of the assets or an increase in the fair value of the liabilities from the preliminary valuations presented would result in a dollar-for-dollar corresponding increase in the amount of goodwill that will result from the DERMAdoctor Acquisition. In addition, if the value of the property and equipment and identifiable intangible assets is higher than the amounts included in these unaudited pro forma condensed combined financial statements, it may result in higher depreciation and amortization expense than is presented in the unaudited pro forma condensed combined statements of operations. Any such increases could be material and could result in our actual future financial condition and results of operations differing materially from those presented in the unaudited pro forma condensed combined financial statements.

Note 4. Adjustments to Unaudited Pro Forma Condensed Combined Financial Statements

The unaudited pro forma condensed combined financial information has been prepared to illustrate the effect of the DERMAdoctor Acquisition and has been prepared for informational purposes only. They do not purport to indicate the results of future operations or the financial position of either company.

The historical financial statements have been adjusted in the unaudited pro forma condensed combined financial information to give pro forma effect to events that are directly attributable to the DERMAdoctor Acquisition, factually supportable, and with respect to the statements of operations, expected to have a continuing impact on the results of NovaBay. ****

The following items are presented as reclassifications in the unaudited pro forma condensed combined financial statements for purposes of conforming DERMAdoctor’s classification of certain assets, liabilities, income, and expenses to our presentation for the combined presentation:

(a)	Adjustment includes preliminary estimated fair value of intangible assets acquired by NovaBay.
(b)	Adjustment reflects preliminary estimated goodwill.
---	---
(c)	Adjustment reflects the preliminary estimated fair value of the Earn Out Payments of $750 thousand. This contingent consideration is included in the preliminary estimated fair value of the consideration transferred in the DERMAdoctor Acquisition.
---	---
(d)	Adjustment offsets related party accounts payable and related party notes payable. These amounts were paid at the Acquisition Closing from the cash portion of the Purchase Price.
---	---
(e)	Adjustment includes the elimination of the historical Members’ Deficit of DERMAdoctor and the preliminary cumulative impact of the amortization of identifiable intangible assets.
---	---
(f)	These adjustments reclassify certain amounts set forth under the line item “Selling expenses” in DERMAdoctor’s audited and unaudited financial statements to “Product revenue, net” in the unaudited pro forma condensed combined statements of operations to conform to NovaBay’s presentation.
---	---
(g)	Adjustment includes pro forma accounting adjustment for DERMAdoctor’s Paycheck Protection Program Loan (PPP Loan) forgiveness amount to conform to NovaBay’s presentation. The PPP Loan was forgiven on September 3, 2021.
---	---
(h)	Represents pro forma adjustment to eliminate transaction expenses related to the DERMAdoctor Acquisition incurred by NovaBay and DERMAdoctor.
---	---
(i)	Includes the cumulative impact of preliminary amortization expense of approximately $370,000 for identifiable intangible assets acquired.
---	---
(j)	Represents gross proceeds of $15.0 million from the Private Placement in which the Company issued 15,000 shares of Preferred Stock, together with the Warrants at a price of $1,000 per share, less approximately $1,625,000 in preliminary estimated placement agent, attorney and other offering expenses paid in connection with the Private Placement.
---	---